Form 4: Orchestra BioMed CEO Buys 6,000 Shares

Orchestra BioMed Holdings, Inc. CEO and Chairperson David P. Hochman purchased 6,000 shares of common stock at an average price of $2.49.

Summary

• David P. Hochman, the Chief Executive Officer and Chairperson of Orchestra BioMed Holdings, Inc. (OBIO), acquired 6,000 shares of the company's common stock.
• The transaction took place on August 21, 2025, at a weighted average price of $2.49 per share, with individual purchase prices ranging from $2.49 to $2.50.
• This purchase was made pursuant to a Rule 10b5-1(c) pre-arranged trading plan.
• Following this acquisition, Mr. Hochman directly beneficially owns 651,460 shares of common stock.
• Additionally, Mr. Hochman indirectly beneficially owns 458,471 shares through various trusts, including 449,331 shares via the DPH 2008 Trust, 2,000 shares via the Solomon Ascher Hochman 2019 Trust, 2,000 shares via the Hannah Hochman 2019 Trust, 2,000 shares via the Judah Herman Hochman 2019 Trust, and 3,140 shares via the NSH 2008 Family Trust.

Sentiment

Score: 8

Explanation: The purchase of shares by the CEO and Chairperson, especially under a 10b5-1 plan, indicates strong insider confidence in the company's valuation and future prospects, which is a significant positive signal for investors.

Positives

• The purchase of 6,000 shares by the CEO and Chairperson, David P. Hochman, signals strong insider confidence in Orchestra BioMed's future prospects and valuation.
• The transaction was executed under a Rule 10b5-1 plan, indicating a pre-planned investment strategy rather than a reactive market decision.

Future Outlook

The filing itself does not provide a future outlook, but the insider purchase by the CEO and Chairperson can be interpreted as a positive signal regarding the company's future performance and valuation.

Industry Context

Insider buying, particularly by a company's CEO and Chairperson, is generally viewed as a strong positive indicator across all industries, suggesting that management believes the company's stock is undervalued or expects significant positive developments.

Comparison to Industry Standards

• Insider purchases by top executives, such as the CEO, are typically considered a more robust signal of confidence compared to purchases by other insiders or open market transactions by institutional investors.
• The execution of the purchase under a Rule 10b5-1 plan aligns with best practices for insiders to manage their stock transactions in a pre-planned and compliant manner, reducing concerns about opportunistic trading.

Stakeholder Impact

• Shareholders: The insider purchase may instill confidence among existing shareholders and attract new investors, potentially leading to positive share price movement due to perceived management conviction.

Key Dates

Recommendation

The CEO and Chairperson, David P. Hochman, purchasing a significant number of shares (6,000) at market prices, especially under a pre-arranged 10b5-1 plan, demonstrates strong conviction in the company's value and future performance. This insider confidence is a compelling indicator for potential investors, suggesting a 'buy' recommendation.

Keywords

Orchestra BioMed, OBIO, Insider Trading, Stock Purchase, CEO, David P. Hochman, Form 4, Equity Acquisition, 10b5-1 Plan